AlloVir Inc. (ALVR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALVR Stock Price Chart Interactive Chart >
ALVR Price/Volume Stats
| Current price | $3.76 | 52-week high | $26.41 |
| Prev. close | $3.61 | 52-week low | $3.21 |
| Day low | $3.42 | Volume | 245,700 |
| Day high | $3.80 | Avg. volume | 1,236,128 |
| 50-day MA | $5.51 | Dividend yield | N/A |
| 200-day MA | $13.72 | Market Cap | 245.97M |
AlloVir Inc. (ALVR) Company Bio
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.
Latest ALVR News From Around the Web
Below are the latest news stories about Allovir Inc that investors may wish to consider to help them evaluate ALVR as an investment opportunity.
Rate - Zacks Investment Research Lowers AlloVir to SellZacks Investment Research cut shares of AlloVir from a hold rating to a sell rating in a report published on Friday morning, Zacks.com reports. According to Zacks, “AlloVir… |
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay will be availa |
Recap: AlloVir Q4 EarningsAlloVir (NASDAQ: ALVR ) reported its Q4 earnings results on Thursday, February 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Check out this: Insiders Buy Over $43M Of 4 Stocks Earnings AlloVir … Full story available on Benzinga.com |
AlloVir Reports Full-Year 2021 Financial Results and 2022 OutlookWALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections |
AlloVir GAAP EPS of -$2.74 misses by $0.10AlloVir press release (ALVR): FY GAAP EPS of -$2.74 misses by $0.10.As of December 31, 2021, company had cash, cash equivalents and marketable securities of $248.1 million, compared… |
ALVR Price Returns
| 1-mo | -17.36% |
| 3-mo | -58.22% |
| 6-mo | -78.47% |
| 1-year | -83.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -70.94% |
| 2021 | -66.34% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...